Novartis publishes Q2 impact and sustainability update to investors

Novartis outlined a sustainability-focused operations strategy that ties its 2040 net-zero goal to product design, manufacturing, sourcing, and supply chain decisions.

• Scope 3 emissions cut 17% versus a 2022 baseline by 2025, leaving a 25% reduction to meet the 2030 target; purchased goods drive about 80%.
• Life-cycle assessments flagged drug-substance manufacturing as the main emissions hotspot, prompting supplier actions on process efficiency, renewables, logistics, and packaging.
• Water stewardship plan targets no water-quality impacts from manufacturing effluents by 2030; 2025 compliance reached 97% of sites, 100% of in-scope suppliers.
• Investor engagement flagged AI as a priority topic; an AI-focused Meet Novartis Management session is scheduled for Nov. 19, 2026.